CTXR;Biotech Home Investing Sector News Wal
Post# of 103036
(Total Views: 547)
Posted On: 06/07/2017 10:12:52 AM
CTXR;Biotech
Home
Investing
Sector News
Wall Street Daily
Opinion
HOME ABOUT US OUR TEAM CONTACT US
OracleDispatch.comOracle Dispatch
HOME
INVESTING
SECTOR NEWS
WALL STREET DAILY
OPINION
Home Citius Pharmaceuticals Inc (CTXR:OTCQB) On Immediate Alert – Pharma Break-Out Pick
Citius Pharmaceuticals Inc (CTXR:OTCQB) On Immediate Alert – Pharma Break-Out Pick
Presently Citius Pharmaceuticals Inc CTXR:OTCQB has 2 drugs in late stage development (one product in Phase 3 of FDA approval, and another in Phase 2) that could catapult this entire situation into a whole new stratosphere!
ArrowMorning Traders,
I hope you are fired up and ready today. The last time we alerted CTXR 2 months ago popped 62.7% profit in 2 days!
Guess what? It’s flashing the same signals again. Read This Report.
We are Issuing an Immediate Alert on Citius Pharmaceuticals (CTXR)
CTXR is about as an exciting as a situation as I have ever seen in small caps; this is an undiscovered runner in the booming biotech field that has really big names behind it and is well funded moving forward.
BIOTECHS are about as explosive as it gets on the OTC and CTXR is no exception. Over the past 3 months alone CTXR has popped to $1 for over 100% move on 3 separate occasions. (Any time any news comes) Now that CTXR is back at $0.45 we are all over it in anticipation of the next run to $1.
CTXR started moving this week! CTXR was up as much as 12% on a massive surge of volume today!
Currently CTXR has 2 drugs in late stage development (one product in Phase 3 of FDA approval, and another in Phase 2) that could catapult this entire situation into a whole new stratosphere!
Citius Pharmaceuticals; CTXR is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.
Last year CTXR completed the acquisition of Leonard-Meron Biosciences, Inc. (“LMB”) LMB’s leading drug candidate, Mino-Lok™, is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (“CRBSIs”). Mino-Lok™ is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilm, eradicate the bacteria, provide anti-clotting properties to maintain patency, and salvage the indwelling central venous catheter (“CVC”).
Mino-Lok™ is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration (“FDA”) granted a Qualified Infectious Disease Product (“QIDP”) designation for Mino-Lok™. Receiving QIDP designation means that Mino-Lok™ is now eligible for Fast Track designation, Priority Review, and a five-year extension of market exclusivity. CEO Leonard Mazur said “Management is excited with the acquisition which has provided us immediate access to Mino-Lok™, a phase 3 ready program in a billion-dollar industry,”
CTXR hydrocortisone and lidocaine cream is targeting to become the first FDA –approved prescription product to treat hemorrhoids in the U.S.
In December CTXR provided details of its phase 3 trial for Mino-Lok™ Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI) in combination with appropriate systemic antibiotic(s), to salvage infected CVCs, to preserve central venous access, and to avoid the complications and morbidities associated with catheter removal and reinsertion.
Clinical trial startup activities are underway and Citius is recruiting and qualifying sites for the trial. The first patient is expected to be enrolled in early 2017.
CTXR Market Outlook:
The market potential of CTXR Hydrocortisone and Lidocaine Combination Cream is massive. Nearly 50% of adults will have experienced the pain, discomfort, itching, and bleeding associated with hemorrhoids at least once.
In the U.S. an estimated 10 million patients report symptoms of hemorrhoidal disease each year. According to IMS, over 25 million units of topical combination prescription products for hemorrhoids were sold in the United States. During the twelve-month period ended June 2012, comprising an estimated $80 million annual market.
The market potential for Mino-Lok™ is a billion dollar market. There is an important need to develop an alternative to the standard of care for catheter-related blood stream infections (CRBSIs). Of the approximately 7 million central venous catheters (CVCs) used annually, about 500,000 or 7% become infected leading to serious, life threatening infections.
The standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly and 15% to 20% of the procedures are associated with significant morbidity. There are currently no approved therapies to salvage infected CVCs.
CTXR has a highly compelling chart setup here! Currently base lined at its $0.50 support levels CTXR has made no less than 3 separate runs to the $1 level over the past –. Every time any news comes on CTXR the stock has exploded over 100% in the last 3 months and we are looking for it to do it again!
Everyone knows just how explosive biotechs can be and CTXR with 2 drugs in late stage development is one good press release away from another explosive RUN!
Citius Pharmaceuticals Inc.
Leonard Mazur
Myron Holubiak
citiuspharma.com
STOCK INFORMATION
SYMBOL: OTCQB: CTXR
Shares Outstanding: 75,504,243
Market Cap: $31,711,782
CTXR has a highly compelling chart setup here! Currently base lined at its $0.45 support levels. A look at the charts shows CTXR has made no less than 3 separate runs to the $1 level over the past 12mo. Every time any news comes on CTXR the stock has exploded over 100% in the last 3 months and we are looking for it to do it again!
CTXR HAS MAMMOTH POTENTIAL HERE:
With all the advances we’ve made in medicine and technology, there are still areas for improvement. For example, there are currently no approved therapies to salvage an infected central venous catheter (CVC). For those unfamiliar with that medical term, WebMd defines it as a long thin, flexible tube used to give medicines, fluids, nutrients, or blood products over a long period of time, usually several weeks or more.
Now, if you sit back and think about it, CVCs are used in various practices of medicine. According to the CDC, one in six central-line infections can be caused by antibiotic-resistant bacteria that is considered a serious or urgent threat. This leaves physicians with few options.
The Center for Infectious Disease Research and Policy published a piece stating that central-line infections are still problematic in US hospitals. In fact, according to Consumer Reports, more than 27K people were struck by central-line infections in 2015. Not only that, but they are fatal in up to a quarter of the cases, and cost $46K to treat on average.
Now, a massive study was released in JAMA Internal Medicine, in which researchers analyzed data on catheter-related bloodstream infections at 113 US hospitals for over a decade. They found out that on average, improved catheter safety measures lowered the cost of treating such infections by $1.85M at each hospital over 3 years.
However, an even better solution could be in the works. There is one small cap company working diligently to come up with the first approved therapy to salvage infected CVCs. Based on the recent performance of their stock price, investors and traders are believing that it might come to fruition.
Citius Pharmaceuticals Inc. (OTCQB:CTXR)
Citius Pharmaceuticals Inc. (OTCQB:CTXR) is a specialty pharmaceutical company that is currently advancing two proprietary product candidates. The first, Mino-Lok™, is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge. In addition, Mino-Lok™ is intended to salvage the CVC obviating the need to remove and replace the catheter. At the moment, there are no alternatives other than the removal and reinsertion of the CVC once the CVC becomes infected. Studies show that removal and reinsertion of CVCs have a 15% to 20% complication rate, including pneumothorax, misplacement, and arterial puncture.
Also, Citius is developing a topical formulation of hydrocortisone (3%) and lidocaine (5%), Hydro-Lido, to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids.
Although there are numerous prescription and over-the-counter products commonly used to treat hemorrhoids, none currently possess safety and efficacy data generated from rigorously conducted clinical trials. Citius believes its hydrocortisone-lidocaine product will become an important treatment option for physicians who want to provide their patients with a therapy that has demonstrated safety and efficacy in treating hemorrhoids. Citius has recently completed a Phase 2a clinical study in 211 hemorrhoid patients.
Citius has designed a phase 3 study for Mino-Lok, after a recent survey showed that catheter salvage in “CLABSI” patients can be highly desirable.
CTXR MANAGEMENT TEAM:
Leonard Mazur, Chairman of the Board, Director: Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Mr. Mazur received both his BA and MBA from Temple University and has served in the U.S. Marine Corps Reserves.
Myron Holubiak, President and Chief Executive Officer, Director: Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London; and, advanced training in health economics from the University of York’s Centre for Health Economics.
Gary F. Talarico, EVP, Operations: Mr. Talarico has served as EVP, Operations since March 2016. Mr. Talarico has successfully built and led all commercial activities for a number of start-up companies. Mr. Talarico was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Most recently he was a founder, partner and Executive Vice President of Leonard Meron Biosciences; he was instrumental in acquiring its lead product. Mr. Talarico is a graduate of Lewis University
Jaime Bartushak, Chief Financial Officer: Mr. Bartushak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, business development, restructuring, and strategic planning experience. Most recently in 2014, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc. Mr. Bartushak is also one of the founders of Leonard-Meron Biosciences and was instrumental in their startup as well as obtaining initial investment capital.
CTXR RECENT NEWS:
Tuesday, June 6th, 2017
Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational
Thursday, March 23, 2017
Citius Pharma Announces Addition of South America to World License
Friday, February 10, 2017
Citius Pharmaceuticals to Present at BIO CEO & Investor Conference
Thursday, January 12, 2017
Citius Pharma’s Mino-Lok(TM) Inches Closer to Likely FDA Approval
Wednesday, January 11, 2017
Citius’ Mino-Lok™ Addresses Resistant Pathogens
Wednesday, December 21, 2016
Citius Pharmaceuticals to Present at 9th Annual Biotech Showcase
Monday, December 19, 2016
Drug Master File Submitted to FDA for Citius’ Ethanol
Thursday, December 08, 2016
Citius Moves Forward with Mino-Lok™ Phase 3 Trial
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by IMA, Corp. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “IMA” refers to IMA Corp. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated up to $10,000 USD to conduct this investor relations advertising and marketing for CTXR by Third Coast Media, LLC. a third party. IMA’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding the profiled companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IMA often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for human errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
POPULAR POSTS
CNBX
The Path Forward for Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)
June 7, 2017
PNTV
Players Network (OTCMKTS
NTV) is Continuing its Rise
June 7, 2017
GAHC
Global Arena Holding Inc (OTCMKTS:GAHC) Bringing Blockchain to the Voting Booth
June 6, 2017
KGC
Kinross Gold Corporation (USA)(NYSE:KGC) Back on the Rise After Positive Q1...
June 6, 2017
NWBO
Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) Rebooting Under Important Drug Trials
June 6, 2017
GYOG
GREEN ENERGY ENTER COM USD0.01 (OTCMKTS:GYOG) Enters Cannabis Sector as Insurance...
June 6, 2017
UOIP
The Rapid Rise of UnifiedOnline Inc (OTCMKTS:UOIP)
June 6, 2017
SYF
Synchrony Financial (NYSE:SYF) Regains it’s Footing
June 6, 2017
MJNA
Medical Marijuana Inc (OTCMKTS:MJNA) Rallies on Revenue Gain
June 5, 2017
KLGDF
KIRKLAND LAKE GOLD COM NPV (OTCMKTS:KLGDF) Management Shake-Ups Impacting Shareprice
June 5, 2017
OracleDispatch.com
Welcome to the Oracle Dispatch, a free online newspaper packed with exclusive content, news, articles and much more! Each day you’ll receive the latest business and industry news, financial analysis and much more. All this, and it’s free. Join the thousands of Oracle Dispatch users who are already with us! If you have any questions please visit contacts page.
EVEN MORE NEWS
CNBX
The Path Forward for Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)
June 7, 2017
PNTV
Players Network (OTCMKTSNTV) is Continuing its Rise
June 7, 2017
GAHC
Global Arena Holding Inc (OTCMKTS:GAHC) Bringing Blockchain to the Voting Booth
June 6, 2017
POPULAR CATEGORY
Investing
Opinion
Sector News
Wall Street Daily
© Copyright 2016 - Oracle Dispatch. All Rights Reserved
Home
Investing
Sector News
Wall Street Daily
Opinion
HOME ABOUT US OUR TEAM CONTACT US
OracleDispatch.comOracle Dispatch
HOME
INVESTING
SECTOR NEWS
WALL STREET DAILY
OPINION
Home Citius Pharmaceuticals Inc (CTXR:OTCQB) On Immediate Alert – Pharma Break-Out Pick
Citius Pharmaceuticals Inc (CTXR:OTCQB) On Immediate Alert – Pharma Break-Out Pick
Presently Citius Pharmaceuticals Inc CTXR:OTCQB has 2 drugs in late stage development (one product in Phase 3 of FDA approval, and another in Phase 2) that could catapult this entire situation into a whole new stratosphere!
ArrowMorning Traders,
I hope you are fired up and ready today. The last time we alerted CTXR 2 months ago popped 62.7% profit in 2 days!
Guess what? It’s flashing the same signals again. Read This Report.
We are Issuing an Immediate Alert on Citius Pharmaceuticals (CTXR)
CTXR is about as an exciting as a situation as I have ever seen in small caps; this is an undiscovered runner in the booming biotech field that has really big names behind it and is well funded moving forward.
BIOTECHS are about as explosive as it gets on the OTC and CTXR is no exception. Over the past 3 months alone CTXR has popped to $1 for over 100% move on 3 separate occasions. (Any time any news comes) Now that CTXR is back at $0.45 we are all over it in anticipation of the next run to $1.
CTXR started moving this week! CTXR was up as much as 12% on a massive surge of volume today!
Currently CTXR has 2 drugs in late stage development (one product in Phase 3 of FDA approval, and another in Phase 2) that could catapult this entire situation into a whole new stratosphere!
Citius Pharmaceuticals; CTXR is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.
Last year CTXR completed the acquisition of Leonard-Meron Biosciences, Inc. (“LMB”) LMB’s leading drug candidate, Mino-Lok™, is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (“CRBSIs”). Mino-Lok™ is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilm, eradicate the bacteria, provide anti-clotting properties to maintain patency, and salvage the indwelling central venous catheter (“CVC”).
Mino-Lok™ is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration (“FDA”) granted a Qualified Infectious Disease Product (“QIDP”) designation for Mino-Lok™. Receiving QIDP designation means that Mino-Lok™ is now eligible for Fast Track designation, Priority Review, and a five-year extension of market exclusivity. CEO Leonard Mazur said “Management is excited with the acquisition which has provided us immediate access to Mino-Lok™, a phase 3 ready program in a billion-dollar industry,”
CTXR hydrocortisone and lidocaine cream is targeting to become the first FDA –approved prescription product to treat hemorrhoids in the U.S.
In December CTXR provided details of its phase 3 trial for Mino-Lok™ Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI) in combination with appropriate systemic antibiotic(s), to salvage infected CVCs, to preserve central venous access, and to avoid the complications and morbidities associated with catheter removal and reinsertion.
Clinical trial startup activities are underway and Citius is recruiting and qualifying sites for the trial. The first patient is expected to be enrolled in early 2017.
CTXR Market Outlook:
The market potential of CTXR Hydrocortisone and Lidocaine Combination Cream is massive. Nearly 50% of adults will have experienced the pain, discomfort, itching, and bleeding associated with hemorrhoids at least once.
In the U.S. an estimated 10 million patients report symptoms of hemorrhoidal disease each year. According to IMS, over 25 million units of topical combination prescription products for hemorrhoids were sold in the United States. During the twelve-month period ended June 2012, comprising an estimated $80 million annual market.
The market potential for Mino-Lok™ is a billion dollar market. There is an important need to develop an alternative to the standard of care for catheter-related blood stream infections (CRBSIs). Of the approximately 7 million central venous catheters (CVCs) used annually, about 500,000 or 7% become infected leading to serious, life threatening infections.
The standard of care in the management of CRBSIs consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. These procedures are costly and 15% to 20% of the procedures are associated with significant morbidity. There are currently no approved therapies to salvage infected CVCs.
CTXR has a highly compelling chart setup here! Currently base lined at its $0.50 support levels CTXR has made no less than 3 separate runs to the $1 level over the past –. Every time any news comes on CTXR the stock has exploded over 100% in the last 3 months and we are looking for it to do it again!
Everyone knows just how explosive biotechs can be and CTXR with 2 drugs in late stage development is one good press release away from another explosive RUN!
Citius Pharmaceuticals Inc.
Leonard Mazur
Myron Holubiak
citiuspharma.com
STOCK INFORMATION
SYMBOL: OTCQB: CTXR
Shares Outstanding: 75,504,243
Market Cap: $31,711,782
CTXR has a highly compelling chart setup here! Currently base lined at its $0.45 support levels. A look at the charts shows CTXR has made no less than 3 separate runs to the $1 level over the past 12mo. Every time any news comes on CTXR the stock has exploded over 100% in the last 3 months and we are looking for it to do it again!
CTXR HAS MAMMOTH POTENTIAL HERE:
With all the advances we’ve made in medicine and technology, there are still areas for improvement. For example, there are currently no approved therapies to salvage an infected central venous catheter (CVC). For those unfamiliar with that medical term, WebMd defines it as a long thin, flexible tube used to give medicines, fluids, nutrients, or blood products over a long period of time, usually several weeks or more.
Now, if you sit back and think about it, CVCs are used in various practices of medicine. According to the CDC, one in six central-line infections can be caused by antibiotic-resistant bacteria that is considered a serious or urgent threat. This leaves physicians with few options.
The Center for Infectious Disease Research and Policy published a piece stating that central-line infections are still problematic in US hospitals. In fact, according to Consumer Reports, more than 27K people were struck by central-line infections in 2015. Not only that, but they are fatal in up to a quarter of the cases, and cost $46K to treat on average.
Now, a massive study was released in JAMA Internal Medicine, in which researchers analyzed data on catheter-related bloodstream infections at 113 US hospitals for over a decade. They found out that on average, improved catheter safety measures lowered the cost of treating such infections by $1.85M at each hospital over 3 years.
However, an even better solution could be in the works. There is one small cap company working diligently to come up with the first approved therapy to salvage infected CVCs. Based on the recent performance of their stock price, investors and traders are believing that it might come to fruition.
Citius Pharmaceuticals Inc. (OTCQB:CTXR)
Citius Pharmaceuticals Inc. (OTCQB:CTXR) is a specialty pharmaceutical company that is currently advancing two proprietary product candidates. The first, Mino-Lok™, is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge. In addition, Mino-Lok™ is intended to salvage the CVC obviating the need to remove and replace the catheter. At the moment, there are no alternatives other than the removal and reinsertion of the CVC once the CVC becomes infected. Studies show that removal and reinsertion of CVCs have a 15% to 20% complication rate, including pneumothorax, misplacement, and arterial puncture.
Also, Citius is developing a topical formulation of hydrocortisone (3%) and lidocaine (5%), Hydro-Lido, to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids.
Although there are numerous prescription and over-the-counter products commonly used to treat hemorrhoids, none currently possess safety and efficacy data generated from rigorously conducted clinical trials. Citius believes its hydrocortisone-lidocaine product will become an important treatment option for physicians who want to provide their patients with a therapy that has demonstrated safety and efficacy in treating hemorrhoids. Citius has recently completed a Phase 2a clinical study in 211 hemorrhoid patients.
Citius has designed a phase 3 study for Mino-Lok, after a recent survey showed that catheter salvage in “CLABSI” patients can be highly desirable.
CTXR MANAGEMENT TEAM:
Leonard Mazur, Chairman of the Board, Director: Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Mr. Mazur received both his BA and MBA from Temple University and has served in the U.S. Marine Corps Reserves.
Myron Holubiak, President and Chief Executive Officer, Director: Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London; and, advanced training in health economics from the University of York’s Centre for Health Economics.
Gary F. Talarico, EVP, Operations: Mr. Talarico has served as EVP, Operations since March 2016. Mr. Talarico has successfully built and led all commercial activities for a number of start-up companies. Mr. Talarico was a founder and Executive Vice President of Sales and Marketing for Reliant Pharmaceuticals, LLC; Reliant was later sold to GlaxoSmithKline plc. Most recently he was a founder, partner and Executive Vice President of Leonard Meron Biosciences; he was instrumental in acquiring its lead product. Mr. Talarico is a graduate of Lewis University
Jaime Bartushak, Chief Financial Officer: Mr. Bartushak is an experienced finance professional for early stage pharmaceutical companies, and has over 20 years of corporate finance, business development, restructuring, and strategic planning experience. Most recently in 2014, Mr. Bartushak helped lead the sale of PreCision Dermatology, Inc. to Valeant Pharmaceuticals International, Inc. Mr. Bartushak is also one of the founders of Leonard-Meron Biosciences and was instrumental in their startup as well as obtaining initial investment capital.
CTXR RECENT NEWS:
Tuesday, June 6th, 2017
Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational
Thursday, March 23, 2017
Citius Pharma Announces Addition of South America to World License
Friday, February 10, 2017
Citius Pharmaceuticals to Present at BIO CEO & Investor Conference
Thursday, January 12, 2017
Citius Pharma’s Mino-Lok(TM) Inches Closer to Likely FDA Approval
Wednesday, January 11, 2017
Citius’ Mino-Lok™ Addresses Resistant Pathogens
Wednesday, December 21, 2016
Citius Pharmaceuticals to Present at 9th Annual Biotech Showcase
Monday, December 19, 2016
Drug Master File Submitted to FDA for Citius’ Ethanol
Thursday, December 08, 2016
Citius Moves Forward with Mino-Lok™ Phase 3 Trial
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by IMA, Corp. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “IMA” refers to IMA Corp. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated up to $10,000 USD to conduct this investor relations advertising and marketing for CTXR by Third Coast Media, LLC. a third party. IMA’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding the profiled companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IMA often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for human errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
POPULAR POSTS
CNBX
The Path Forward for Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)
June 7, 2017
PNTV
Players Network (OTCMKTS
NTV) is Continuing its Rise June 7, 2017
GAHC
Global Arena Holding Inc (OTCMKTS:GAHC) Bringing Blockchain to the Voting Booth
June 6, 2017
KGC
Kinross Gold Corporation (USA)(NYSE:KGC) Back on the Rise After Positive Q1...
June 6, 2017
NWBO
Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) Rebooting Under Important Drug Trials
June 6, 2017
GYOG
GREEN ENERGY ENTER COM USD0.01 (OTCMKTS:GYOG) Enters Cannabis Sector as Insurance...
June 6, 2017
UOIP
The Rapid Rise of UnifiedOnline Inc (OTCMKTS:UOIP)
June 6, 2017
SYF
Synchrony Financial (NYSE:SYF) Regains it’s Footing
June 6, 2017
MJNA
Medical Marijuana Inc (OTCMKTS:MJNA) Rallies on Revenue Gain
June 5, 2017
KLGDF
KIRKLAND LAKE GOLD COM NPV (OTCMKTS:KLGDF) Management Shake-Ups Impacting Shareprice
June 5, 2017
OracleDispatch.com
Welcome to the Oracle Dispatch, a free online newspaper packed with exclusive content, news, articles and much more! Each day you’ll receive the latest business and industry news, financial analysis and much more. All this, and it’s free. Join the thousands of Oracle Dispatch users who are already with us! If you have any questions please visit contacts page.
EVEN MORE NEWS
CNBX
The Path Forward for Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)
June 7, 2017
PNTV
Players Network (OTCMKTS
NTV) is Continuing its Rise June 7, 2017
GAHC
Global Arena Holding Inc (OTCMKTS:GAHC) Bringing Blockchain to the Voting Booth
June 6, 2017
POPULAR CATEGORY
Investing
Opinion
Sector News
Wall Street Daily
© Copyright 2016 - Oracle Dispatch. All Rights Reserved
(0)
(0)Scroll down for more posts ▼